The results showed that compared with the acute pancreatitis group, pancreatic edema, acinous necrosis, inflammatory infiltration and perivascular infiltration were significantly reduced in the treatment group, and the pancreatic injury score was decreased (Fig. 8C and D), suggesting that Prdx4 may be a therapeutic target for AP. The gene discussed is PRDX4; the disease is acute pancreatitis.